Astragaloside IV remodels gastric inflammation-cancer transformation by modulating the CXCL5-CXCR2 axis-mediated epithelial-mesenchymal transition - PubMed
5 hours ago
- #traditional Chinese medicine
- #inflammation-cancer transformation
- #gastric cancer
- Astragaloside IV (AS-IV) modulates the CXCL5-CXCR2 axis to prevent gastric inflammation-cancer transformation.
- CXCL5 and CXCR2 levels are elevated in chronic atrophic gastritis (CAG) and gastric cancer (GC), correlating with disease severity.
- The CXCL5/CXCR2 axis promotes EMT via ERK/Elk-1 pathway activation, driving inflammation-to-cancer progression.
- AS-IV disrupts CXCL5-CXCR2 interaction, inhibits downstream signaling, and suppresses EMT, showing therapeutic potential for CAG and GC.
- Study combines clinical samples, in vitro models (GES-1, MKN45 cells), and in vivo models (SD rats, BALB/c nude mice) for comprehensive analysis.